Clinical Trials Logo
  1. Home
  2. Healthy Eyes
  3. NCT06071546

Clinical Investigation of a New Version of MAIA Microperimeter on Healthy Subjects and Patients With Retinal Pathology

Retinal Diseases Clinical Trial

Official title:
Pre-market Monocentric Cross-sectional Clinical Investigation of MAIA on Healthy Subjects and Patients With Retinal Pathology: Agreement With MAIA 2013 EDITION Microperimeter and Repeatability Evaluation

Clinical Trial Summary

The purpose of this pre-market, monocentric cross-sectional study is to evaluate the clinical usefulness of a new version of the MAIA device (MAIA) through an agreement with the established version of the MAIA microperimeter (MAIA 2013 EDITION). Moreover, the study aims to evaluate MAIA test-retest repeatability in comparison with MAIA 2013 EDITION and to evaluate MAIA safety and adverse events. These purposes will be achieved by collecting data of healthy subjects and patients with retinal pathology. All participants will undergo repeated microperimetric examinations with both devices during one single visit.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06071546
Study type Interventional
Source Centervue SpA
Contact
Status Active, not recruiting
Phase N/A
Start date October 17, 2023
Completion date September 17, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04968756 - Evaluating the Safety of the SPECTRALIS CENTAURUS Device N/A
Recruiting NCT01521065 - An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration Phase 2
Completed NCT00437593 - UHR-OCT and HD-OCT for Preretinal Membranes: ICG Versus Membrane Blue N/A
Completed NCT04919473 - Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa Phase 1/Phase 2
Terminated NCT01225146 - Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2) Phase 1
Completed NCT01205035 - High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia Phase 2
Completed NCT00812760 - Effect of Levodopa on Human Multifocal Electroretinogram Phase 4
Completed NCT02946879 - Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)
Completed NCT01016873 - INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD Phase 2
Recruiting NCT04592068 - AI Classifies Multi-Retinal Diseases
Completed NCT01746563 - Intravitreal Ranibizumab Combined With Panretinal Photocoagulation in Patients With Proliferative Diabetic Retinopathy Phase 1/Phase 2
Completed NCT01399515 - Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa Phase 2
Terminated NCT02348359 - X-82 to Treat Age-related Macular Degeneration Phase 2
Completed NCT03954626 - Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD Phase 3
Completed NCT02582164 - Long-Working Distance OCT for Children N/A
Completed NCT01790958 - Microcurrent Stimulation to Treat Macular Degeneration N/A
Recruiting NCT05283941 - Pistachios and Neural Macular Pigment N/A
Completed NCT04678375 - Artificial Intelligence for Detecting Retinal Diseases
Completed NCT04902170 - Long-shaft Vitrectomy Probe in Highly Myopic Eyes N/A
Completed NCT02646670 - Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema Phase 4